Ex vivo evaluation of acellular and cellular collagen-glycosaminoglycan flowable matrices.

T Hodgkinson; A. Bayat

doi:10.1088/1748-6041/10/4/041001

Ex vivo evaluation of acellular and cellular collagen-glycosaminoglycan flowable matrices.

T Hodgkinson, A. Bayat

Research output: Contribution to journal › Article › peer-review

Abstract

Collagen-glycosaminoglycan flowable matrices (CGFM) are increasingly finding utility in a diversifying number of cutaneous surgical procedures. Cellular in-growth and vascularisation of CGFM remain rate-limiting steps, increasing cost and decreasing efficacy. Through in vitro and ex vivo culture methods, this study investigated the improvement of injectable CGFM by the incorporation of hyaluronan (HA) and viable human cells (primary human dermal fibroblasts (PHDFs) and bone marrow-derived mesenchymal stem cells (BM-MSCs)). Ex vivo investigations included the development and evaluation of a human cutaneous wound healing model for the comparison of dermal substitutes. Cells mixed into the Integra Flowable Wound Matrix (IFWM), a commercially available CGFM, were confirmed to be viable and proliferative through MTT assays (p

Original language	English
Pages (from-to)	1-8
Number of pages	7
Journal	Biomedical Materials (Bristol)
Volume	10
Issue number	4
DOIs	https://doi.org/10.1088/1748-6041/10/4/041001
Publication status	Published - 16 Jul 2015

Keywords

wound healing
ex vivo wound models
whole skin organ culture
hylaloronic acid

Access to Document

10.1088/1748-6041/10/4/041001

Cite this

@article{29859178fc9b4bc5949efa1d01690c5d,

title = "Ex vivo evaluation of acellular and cellular collagen-glycosaminoglycan flowable matrices.",

abstract = "Collagen-glycosaminoglycan flowable matrices (CGFM) are increasingly finding utility in a diversifying number of cutaneous surgical procedures. Cellular in-growth and vascularisation of CGFM remain rate-limiting steps, increasing cost and decreasing efficacy. Through in vitro and ex vivo culture methods, this study investigated the improvement of injectable CGFM by the incorporation of hyaluronan (HA) and viable human cells (primary human dermal fibroblasts (PHDFs) and bone marrow-derived mesenchymal stem cells (BM-MSCs)). Ex vivo investigations included the development and evaluation of a human cutaneous wound healing model for the comparison of dermal substitutes. Cells mixed into the Integra Flowable Wound Matrix (IFWM), a commercially available CGFM, were confirmed to be viable and proliferative through MTT assays (p ",

keywords = "wound healing, ex vivo wound models, whole skin organ culture, hylaloronic acid",

author = "T Hodgkinson and A. Bayat",

year = "2015",

month = jul,

day = "16",

doi = "10.1088/1748-6041/10/4/041001",

language = "English",

volume = "10",

pages = "1--8",

journal = "Biomedical Materials (Bristol)",

issn = "1748-6041",

publisher = "IOP Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Ex vivo evaluation of acellular and cellular collagen-glycosaminoglycan flowable matrices.

AU - Hodgkinson, T

AU - Bayat, A.

PY - 2015/7/16

Y1 - 2015/7/16

N2 - Collagen-glycosaminoglycan flowable matrices (CGFM) are increasingly finding utility in a diversifying number of cutaneous surgical procedures. Cellular in-growth and vascularisation of CGFM remain rate-limiting steps, increasing cost and decreasing efficacy. Through in vitro and ex vivo culture methods, this study investigated the improvement of injectable CGFM by the incorporation of hyaluronan (HA) and viable human cells (primary human dermal fibroblasts (PHDFs) and bone marrow-derived mesenchymal stem cells (BM-MSCs)). Ex vivo investigations included the development and evaluation of a human cutaneous wound healing model for the comparison of dermal substitutes. Cells mixed into the Integra Flowable Wound Matrix (IFWM), a commercially available CGFM, were confirmed to be viable and proliferative through MTT assays (p

AB - Collagen-glycosaminoglycan flowable matrices (CGFM) are increasingly finding utility in a diversifying number of cutaneous surgical procedures. Cellular in-growth and vascularisation of CGFM remain rate-limiting steps, increasing cost and decreasing efficacy. Through in vitro and ex vivo culture methods, this study investigated the improvement of injectable CGFM by the incorporation of hyaluronan (HA) and viable human cells (primary human dermal fibroblasts (PHDFs) and bone marrow-derived mesenchymal stem cells (BM-MSCs)). Ex vivo investigations included the development and evaluation of a human cutaneous wound healing model for the comparison of dermal substitutes. Cells mixed into the Integra Flowable Wound Matrix (IFWM), a commercially available CGFM, were confirmed to be viable and proliferative through MTT assays (p

KW - wound healing

KW - ex vivo wound models

KW - whole skin organ culture

KW - hylaloronic acid

U2 - 10.1088/1748-6041/10/4/041001

DO - 10.1088/1748-6041/10/4/041001

M3 - Article

SN - 1748-6041

VL - 10

SP - 1

EP - 8

JO - Biomedical Materials (Bristol)

JF - Biomedical Materials (Bristol)

IS - 4

ER -

Ex vivo evaluation of acellular and cellular collagen-glycosaminoglycan flowable matrices.

Abstract

Keywords

Access to Document

Fingerprint

Cite this